Perimeter Medical Imaging Ai Inc Stock Price, News & Analysis

Perimeter Medical Imaging AI (OTCQX:PYNKF) announced that Medical City Dallas Hospital, an 899-bed acute care facility, has adopted their S-Series OCT imaging technology for surgical procedures. This adoption follows the hospital's participation in a pivotal trial of Perimeter's next-generation B-Series device, which combines OCT with AI technology for breast-conserving surgeries.

The S-Series OCT technology, FDA-cleared in 2021, provides high-resolution visualization of tissue microstructures at the cellular level, offering superior imaging capabilities compared to traditional methods like X-ray, MRI, or ultrasound. The system is optimized to identify regions of interest in tissue microstructures down to 2mm, making it particularly effective for visualizing surgical margins.

Perimeter Medical Imaging AI (PYNKF) announced that CEO Adrian Mendes will deliver a business update presentation at the Life Sciences Virtual Investor Forum on June 12, 2025, at 12:30 p.m. Eastern Time. The commercial-stage medical technology company will make the presentation available via live stream, which will be accessible through their website's Investors section and archived for approximately 90 days.

Perimeter Medical Imaging AI has launched the OCT-Tissue Surveillance Registry, a database aimed at collecting thousands of surgical procedure images and data using their imaging technology. The registry will support future product development and enhance their AI deep-learning model. The company's S-Series OCT technology provides real-time, ultra-high resolution visualization of tissue specimens during surgery. Their next-generation B-Series OCT with ImgAssist AI 2.0, currently under FDA review, integrates AI to help detect suspicious tissue during breast-conserving surgery. Dr. Jennifer Tittensor, who has used the technology in over 120 surgeries, highlighted its value in assessing margins in real-time. The registry will help gather diverse patient data to improve AI algorithm training, potentially leading to more personalized care and reduced need for second surgeries.

Perimeter Medical Imaging AI (TSXV: PINK, OTCQX: PYNKF) has partnered with Intermountain Health, the largest nonprofit health system in the Intermountain West, through a Development Support Agreement (DSA). The collaboration aims to study the value of Perimeter's Optical Coherence Tomography (OCT) technology and gather data for AI algorithm development.

The initial study will analyze reoperation rates and healthcare costs for breast-conserving surgery (BCS) patients at select hospitals. The partnership will support Perimeter's FDA PMA approval process for their AI-enabled OCT system and potential expansion into other tissue types beyond breast surgery.

Perimeter Medical Imaging AI (TSX-V: PINK) (OTCQX: PYNKF), a commercial-stage medical technology company, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025, after market close. The company will host a conference call and webcast at 5:00 pm Eastern Time to discuss the results and provide a corporate update. Investors can access the call via 1-800-717-1738 (Canada/US) or 1-646-307-1865 (International). The webcast will be available live and archived on Perimeter's website in the Investors section under "News/Events".

Perimeter Medical Imaging AI presented detailed results from their pivotal trial of B-Series OCT with ImgAssist AI 2.0 for breast cancer surgery margin assessment at ASBrS 2025. The trial met its primary endpoint with statistically significant results (p=0.0050), demonstrating super-superiority compared to standard care. Key findings include: - Among 206 patients, the system correctly detected residual disease in 40% of cases (14/35 patients) after standard care - Completely cleared residual disease in 20% of additional patients - Achieved 88.1% overall margin accuracy - Required minimal additional tissue removal (only 3.8% of total volume) - Benefited 26 patients clinically, including 6 cases where the system detected disease missed by both standard care and histopathology The company has submitted a Premarket Approval application to the FDA in March 2025 for use during breast-conserving surgeries.

Perimeter Medical Imaging AI announced that HonorHealth, a major healthcare system in Phoenix and Scottsdale, has become Arizona's first to implement their S-Series OCT technology for visualizing tissue margins during surgery.

The groundbreaking Optical Coherence Tomography technology offers superior resolution compared to traditional imaging methods, enabling visualization at the cellular level. It creates 3D images with 10 times the resolution of ultrasound and X-ray, and 100 times that of MRI, helping surgeons make real-time decisions during procedures.

Key advantages include:

• 2mm resolution optimization for tissue microstructures
• Real-time visualization of surgical margins
• FDA clearance for general tissue imaging since 2021

This deployment represents a significant expansion of Perimeter's commercial presence in the Southwest, potentially reducing the need for follow-up surgeries that typically result from waiting up to 10 days for traditional pathology results.

Perimeter Medical Imaging AI (TSXV: PINK) (OTCQX: PYNKF), a commercial-stage medical technology company, has announced its upcoming participation at the 2025 Bloom Burton & Co. Healthcare Investor Conference.

Key details:

• Event Date: Monday, May 5, 2025
• Time: 9:30 a.m. Eastern Time
• Location: Metro Toronto Convention Centre

The company's management will deliver a business update presentation at the conference. For those unable to attend in person, the presentation will be available through a live broadcast and will also be archived on the company's website. Interested parties can access the presentation recording in the "News/Events" section under the Investors tab of Perimeter's website.

Perimeter Medical Imaging AI (PYNKF) reported its Q4 and full-year 2024 financial results, highlighting significant commercial growth. The company achieved nine new S-Series OCT system placements in 2024, up from three in 2023, with Q4-2024 revenues increasing 303% year-over-year to $293,000.

The company's pivotal study for its next-generation B-Series OCT with ImgAssist AI 2.0 met its primary endpoint, demonstrating statistically significant reduction in patients with residual cancer during breast-conserving surgeries. Perimeter recently submitted a Premarket Approval (PMA) application to the FDA for this technology.

Financial highlights for FY2024 include:

• Revenue of $846,000, up 110% from 2023
• Operating expenses of $19.4 million
• Net loss of $13.4 million ($0.19 per share)
• Cash position of $6.2 million as of December 31, 2024
• Additional $2.0 million CPRIT grant receivable